2.4 Epinephrine Dosing & Pharmacodynamics in Arrest

2.4 Epinephrine Dosing & Pharmacodynamics in Arrest

Epinephrine is the primary vasopressor utilized in the Advanced Cardiovascular Life Support (ACLS) algorithms for the management of cardiac arrest. Regardless of the underlying rhythm, epinephrine is a foundational pharmacological intervention designed to optimize hemodynamics during cardiopulmonary resuscitation (CPR). Understanding its dosing, physiological mechanisms, and the critical timing of its administration is essential for maximizing a patient's chances of Return of Spontaneous Circulation (ROSC).

Standard Dosing and Administration

During cardiac arrest, the standard dose of epinephrine is 1 mg administered intravenously (IV) or intraosseously (IO).

• This dose should be repeated every 3 to 5 minutes as long as the patient remains in cardiac arrest.
• Each dose should be followed by a 20 mL flush of normal saline to ensure the medication is rapidly pushed into the central circulation.
• The extremity should be elevated for 10 to 20 seconds after administration to facilitate delivery to the heart.
• If IV/IO access cannot be established, epinephrine can be administered via the endotracheal (ET) tube, though this route is significantly less predictable. The ET dose is typically 2 to 2.5 times the standard IV dose (2 to 2.5 mg) diluted in 5 to 10 mL of sterile water or normal saline.

Pharmacodynamics: How Epinephrine Works

Epinephrine is a naturally occurring catecholamine that stimulates both alpha-adrenergic and beta-adrenergic receptors. In the context of cardiac arrest, its life-saving benefits are primarily driven by its effects on the alpha receptors, while its beta effects can be both helpful and potentially harmful.

Alpha-1 Receptor Stimulation (Vasoconstriction)

The most critical mechanism of action for epinephrine during CPR is its potent stimulation of alpha-1 receptors located in the smooth muscle of blood vessels.

• Vasoconstriction: Alpha-1 stimulation causes profound peripheral vasoconstriction.
• Increased Diastolic Pressure: This peripheral constriction dramatically increases aortic diastolic blood pressure.
• Coronary Perfusion Pressure (CPP): The heart muscle is perfused during the relaxation phase (diastole) of CPR. Coronary Perfusion Pressure is the difference between aortic diastolic pressure and right atrial diastolic pressure. By elevating aortic pressure, epinephrine directly increases CPP.
• Cerebral Perfusion: Similarly, the vasoconstriction shunts blood away from peripheral vascular beds and redirects it to vital organs, specifically improving cerebral perfusion pressure, which is vital for preserving neurologic function.

Without adequate Coronary Perfusion Pressure (generally considered >15 mmHg), ROSC is exceedingly unlikely. Epinephrine is the pharmacological tool used to bridge the gap and maintain this vital perfusion during the mechanical compressions of CPR.

Beta-1 Receptor Stimulation (Chronotropic and Inotropic)

Epinephrine also stimulates beta-1 receptors in the myocardium.

• Chronotropic effect: Increases heart rate.
• Inotropic effect: Increases the force of cardiac contractility.

While these effects are highly beneficial in a beating heart experiencing profound bradycardia or cardiogenic shock, their role during active cardiac arrest is debated. Beta-1 stimulation increases myocardial oxygen demand, which can be detrimental to an already ischemic heart. Furthermore, excessive beta stimulation may increase the risk of recurrent ventricular arrhythmias post-defibrillation. Despite these potential drawbacks, the overwhelming benefit of alpha-1 mediated vasoconstriction makes epinephrine the drug of choice in the arrest algorithms.

Timing Differences: Shockable vs. Non-Shockable Rhythms

The timing of the initial dose of epinephrine depends entirely on whether the patient presents with a shockable rhythm (VF/pVT) or a non-shockable rhythm (Asystole/PEA). This distinction highlights the different physiological priorities in managing these unique arrest scenarios.

Non-Shockable Rhythms (Asystole / PEA)

For patients in Asystole or PEA, the primary issue is a failure of the heart to generate mechanical output, usually secondary to a massive systemic insult (the H's and T's). Because there is no chaotic rhythm to shock back into order, the immediate priority is to chemically force perfusion.

• Timing: Epinephrine should be administered as soon as possible after the onset of cardiac arrest and the initiation of CPR.
• Rationale: Early administration in non-shockable rhythms has been strongly correlated with increased rates of ROSC and survival. The rapid induction of vasoconstriction helps maximize the effectiveness of chest compressions immediately, buying the team time to identify and treat the underlying reversible cause.

Shockable Rhythms (VF / pVT)

For patients in Ventricular Fibrillation or pulseless Ventricular Tachycardia, the primary problem is a chaotic electrical storm that prevents coordinated pumping. The definitive treatment for this is electrical defibrillation, not medication.

• Timing: Epinephrine is not administered immediately. The first priority is to deliver the initial shock and resume CPR. Epinephrine is indicated after the second shock has been delivered, during the subsequent 2-minute cycle of CPR.
• Rationale: The AHA delays epinephrine in the VF/pVT algorithm because early defibrillation is highly effective on its own. Administering epinephrine too early could potentially provoke worse arrhythmias due to its beta-1 properties before the electricity has had a chance to reset the myocardium. If the rhythm remains shockable after two attempts, it indicates refractory VF/pVT, and pharmacological support with epinephrine is then introduced to optimize perfusion and prepare the heart for the third shock.

In summary, epinephrine is a critical component of ACLS. By understanding its strict 3-5 minute dosing schedule, its powerful alpha-1 mediated improvement of coronary perfusion, and the algorithmic timing differences based on the presenting rhythm, providers can use this potent medication effectively to save lives.